Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration

Tokuji Tanaka, Yasutomo Fukunaga, Hiroshi Itoh, Kentaro Doi, Jun Yamashita, Tae Hwa Chun, Mayumi Inoue, Ken Masatsugu, Takatoshi Saito, Naoki Sawada, Satsuki Sakaguchi, Hiroshi Arai, Kazuwa Nakao

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Thiazolidinediones, a new class of antidiabetic drugs that increase insulin sensitivity, have been shown to be ligands for peroxisome proliferator- activated receptor γ (PPARγ). Recent studies demonstrating that PPARγ occurs in macrophages have focused attention on its role in macrophage functions. In this study, we investigated the effect of thiazolidinediones on monocyte proliferation and migration in vitro and the mechanisms involved. In addition, we examined the therapeutic potentials of thiazolidinediones for injured atherosclerotic lesions. Troglitazone and pioglitazone, the two thiazolidinediones, as well as 15-deoxy-Δ12,14- prostaglandin J2 inhibited in a dose-dependent manner the serum-induced proliferation of THP-1 (human monocytic leukemia cells) and of U937 (human monoblastic leukemia cells), which permanently express PPARγ. These ligands for PPARγ also significantly inhibited migration of THP-1 induced by monocyte chemoattractant protein-1 (MCP-1). Troglitazone and 15-deoxy-Δ12,14-prostaglandin J2 significantly suppressed the mRNA expression of the MCP family-specific receptor CCR2 (chemokine CCR2 receptor) in THP-1 at the transcriptional level. Furthermore, troglitazone significantly inhibited MCP-1 binding to THP-1. Oral administration of troglitazone to Watanabe heritable hyperlipidemic (WHHL) rabbits after balloon injury suppressed acute recruitment of monocytes/macrophages and accelerated re- endothelialization. These results suggest that thiazolidinediones have therapeutic potential for the treatment of diabetic vascular complications.

Original languageEnglish
Pages (from-to)255-265
Number of pages11
JournalEuropean Journal of Pharmacology
Volume508
Issue number1-3
DOIs
Publication statusPublished - 2005 Jan 31
Externally publishedYes

Fingerprint

troglitazone
Thiazolidinediones
Peroxisome Proliferator-Activated Receptors
Regeneration
Monocytes
CCR2 Receptors
Chemokine CCL2
pioglitazone
Macrophages
Leukemia
Ligands
Therapeutics
Diabetic Angiopathies
U937 Cells
Chemokine Receptors
Hypoglycemic Agents
Protein Binding
Oral Administration
Insulin Resistance
Rabbits

Keywords

  • CCR2
  • Insulin resistance
  • Macrophage
  • MCP-1
  • PPARγ
  • Thiazolidinedione

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration. / Tanaka, Tokuji; Fukunaga, Yasutomo; Itoh, Hiroshi; Doi, Kentaro; Yamashita, Jun; Chun, Tae Hwa; Inoue, Mayumi; Masatsugu, Ken; Saito, Takatoshi; Sawada, Naoki; Sakaguchi, Satsuki; Arai, Hiroshi; Nakao, Kazuwa.

In: European Journal of Pharmacology, Vol. 508, No. 1-3, 31.01.2005, p. 255-265.

Research output: Contribution to journalArticle

Tanaka, T, Fukunaga, Y, Itoh, H, Doi, K, Yamashita, J, Chun, TH, Inoue, M, Masatsugu, K, Saito, T, Sawada, N, Sakaguchi, S, Arai, H & Nakao, K 2005, 'Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration', European Journal of Pharmacology, vol. 508, no. 1-3, pp. 255-265. https://doi.org/10.1016/j.ejphar.2004.10.056
Tanaka, Tokuji ; Fukunaga, Yasutomo ; Itoh, Hiroshi ; Doi, Kentaro ; Yamashita, Jun ; Chun, Tae Hwa ; Inoue, Mayumi ; Masatsugu, Ken ; Saito, Takatoshi ; Sawada, Naoki ; Sakaguchi, Satsuki ; Arai, Hiroshi ; Nakao, Kazuwa. / Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration. In: European Journal of Pharmacology. 2005 ; Vol. 508, No. 1-3. pp. 255-265.
@article{f04d8ce77eea436da12b4c083dd8014d,
title = "Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration",
abstract = "Thiazolidinediones, a new class of antidiabetic drugs that increase insulin sensitivity, have been shown to be ligands for peroxisome proliferator- activated receptor γ (PPARγ). Recent studies demonstrating that PPARγ occurs in macrophages have focused attention on its role in macrophage functions. In this study, we investigated the effect of thiazolidinediones on monocyte proliferation and migration in vitro and the mechanisms involved. In addition, we examined the therapeutic potentials of thiazolidinediones for injured atherosclerotic lesions. Troglitazone and pioglitazone, the two thiazolidinediones, as well as 15-deoxy-Δ12,14- prostaglandin J2 inhibited in a dose-dependent manner the serum-induced proliferation of THP-1 (human monocytic leukemia cells) and of U937 (human monoblastic leukemia cells), which permanently express PPARγ. These ligands for PPARγ also significantly inhibited migration of THP-1 induced by monocyte chemoattractant protein-1 (MCP-1). Troglitazone and 15-deoxy-Δ12,14-prostaglandin J2 significantly suppressed the mRNA expression of the MCP family-specific receptor CCR2 (chemokine CCR2 receptor) in THP-1 at the transcriptional level. Furthermore, troglitazone significantly inhibited MCP-1 binding to THP-1. Oral administration of troglitazone to Watanabe heritable hyperlipidemic (WHHL) rabbits after balloon injury suppressed acute recruitment of monocytes/macrophages and accelerated re- endothelialization. These results suggest that thiazolidinediones have therapeutic potential for the treatment of diabetic vascular complications.",
keywords = "CCR2, Insulin resistance, Macrophage, MCP-1, PPARγ, Thiazolidinedione",
author = "Tokuji Tanaka and Yasutomo Fukunaga and Hiroshi Itoh and Kentaro Doi and Jun Yamashita and Chun, {Tae Hwa} and Mayumi Inoue and Ken Masatsugu and Takatoshi Saito and Naoki Sawada and Satsuki Sakaguchi and Hiroshi Arai and Kazuwa Nakao",
year = "2005",
month = "1",
day = "31",
doi = "10.1016/j.ejphar.2004.10.056",
language = "English",
volume = "508",
pages = "255--265",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration

AU - Tanaka, Tokuji

AU - Fukunaga, Yasutomo

AU - Itoh, Hiroshi

AU - Doi, Kentaro

AU - Yamashita, Jun

AU - Chun, Tae Hwa

AU - Inoue, Mayumi

AU - Masatsugu, Ken

AU - Saito, Takatoshi

AU - Sawada, Naoki

AU - Sakaguchi, Satsuki

AU - Arai, Hiroshi

AU - Nakao, Kazuwa

PY - 2005/1/31

Y1 - 2005/1/31

N2 - Thiazolidinediones, a new class of antidiabetic drugs that increase insulin sensitivity, have been shown to be ligands for peroxisome proliferator- activated receptor γ (PPARγ). Recent studies demonstrating that PPARγ occurs in macrophages have focused attention on its role in macrophage functions. In this study, we investigated the effect of thiazolidinediones on monocyte proliferation and migration in vitro and the mechanisms involved. In addition, we examined the therapeutic potentials of thiazolidinediones for injured atherosclerotic lesions. Troglitazone and pioglitazone, the two thiazolidinediones, as well as 15-deoxy-Δ12,14- prostaglandin J2 inhibited in a dose-dependent manner the serum-induced proliferation of THP-1 (human monocytic leukemia cells) and of U937 (human monoblastic leukemia cells), which permanently express PPARγ. These ligands for PPARγ also significantly inhibited migration of THP-1 induced by monocyte chemoattractant protein-1 (MCP-1). Troglitazone and 15-deoxy-Δ12,14-prostaglandin J2 significantly suppressed the mRNA expression of the MCP family-specific receptor CCR2 (chemokine CCR2 receptor) in THP-1 at the transcriptional level. Furthermore, troglitazone significantly inhibited MCP-1 binding to THP-1. Oral administration of troglitazone to Watanabe heritable hyperlipidemic (WHHL) rabbits after balloon injury suppressed acute recruitment of monocytes/macrophages and accelerated re- endothelialization. These results suggest that thiazolidinediones have therapeutic potential for the treatment of diabetic vascular complications.

AB - Thiazolidinediones, a new class of antidiabetic drugs that increase insulin sensitivity, have been shown to be ligands for peroxisome proliferator- activated receptor γ (PPARγ). Recent studies demonstrating that PPARγ occurs in macrophages have focused attention on its role in macrophage functions. In this study, we investigated the effect of thiazolidinediones on monocyte proliferation and migration in vitro and the mechanisms involved. In addition, we examined the therapeutic potentials of thiazolidinediones for injured atherosclerotic lesions. Troglitazone and pioglitazone, the two thiazolidinediones, as well as 15-deoxy-Δ12,14- prostaglandin J2 inhibited in a dose-dependent manner the serum-induced proliferation of THP-1 (human monocytic leukemia cells) and of U937 (human monoblastic leukemia cells), which permanently express PPARγ. These ligands for PPARγ also significantly inhibited migration of THP-1 induced by monocyte chemoattractant protein-1 (MCP-1). Troglitazone and 15-deoxy-Δ12,14-prostaglandin J2 significantly suppressed the mRNA expression of the MCP family-specific receptor CCR2 (chemokine CCR2 receptor) in THP-1 at the transcriptional level. Furthermore, troglitazone significantly inhibited MCP-1 binding to THP-1. Oral administration of troglitazone to Watanabe heritable hyperlipidemic (WHHL) rabbits after balloon injury suppressed acute recruitment of monocytes/macrophages and accelerated re- endothelialization. These results suggest that thiazolidinediones have therapeutic potential for the treatment of diabetic vascular complications.

KW - CCR2

KW - Insulin resistance

KW - Macrophage

KW - MCP-1

KW - PPARγ

KW - Thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=19944433644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944433644&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2004.10.056

DO - 10.1016/j.ejphar.2004.10.056

M3 - Article

C2 - 15680279

AN - SCOPUS:19944433644

VL - 508

SP - 255

EP - 265

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -